Literature DB >> 15611259

Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor.

Jameel M Inal1, Kwok-Min Hui, Sylvie Miot, Sigrun Lange, Marcel Ivan Ramirez, Brigitte Schneider, Gerhard Krueger, Jürg-A Schifferli.   

Abstract

The complement system presents a powerful defense against infection and is tightly regulated to prevent damage to self by functionally equivalent soluble and membrane regulators. We describe complement C2 receptor inhibitor trispanning (CRIT), a novel human complement regulatory receptor, expressed on hemopoietic cells and a wide range of tissues throughout the body. CRIT is present in human parasites through horizontal transmission. Serum complement component C2 binds to the N-terminal extracellular domain 1 of CRIT, which, in peptide form, blocks C3 convertase formation and complement-mediated inflammation. Unlike C1 inhibitor, which inhibits the cleavage of C4 and C2, CRIT only blocks C2 cleavage but, in so doing, shares with C1 inhibitor the same functional effect, of preventing classical pathway C3 convertase formation. Ab blockage of cellular CRIT reduces inhibition of cytolysis, indicating that CRIT is a novel complement regulator protecting autologous cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15611259     DOI: 10.4049/jimmunol.174.1.356

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

Review 2.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

3.  Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT.

Authors:  Kwok-Min Hui; George L Orriss; Tilman Schirmer; Bergljót Magnadóttir; Jürg A Schifferli; Jameel M Inal
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

Review 4.  Complement C2 receptor inhibitor trispanning: from man to schistosome.

Authors:  Jameel M Inal
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

Review 5.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

6.  Genome-wide identification of molecular mimicry candidates in parasites.

Authors:  Philipp Ludin; Daniel Nilsson; Pascal Mäser
Journal:  PLoS One       Date:  2011-03-08       Impact factor: 3.240

7.  Characterization of Schistosoma japonicum tetraspanning orphan receptor and its role in binding to complement C2 and immunoprotection against murine schistosomiasis.

Authors:  Shuai Ma; Jinli Zai; Yanhui Han; Yang Hong; Min Zhang; Xiaodan Cao; Qian Han; Ke Lu; Zhixin Zhao; Jiaojiao Lin; Zhiqiang Fu
Journal:  Parasit Vectors       Date:  2017-06-09       Impact factor: 3.876

Review 8.  The Complement System: A Prey of Trypanosoma cruzi.

Authors:  Kárita C F Lidani; Lorena Bavia; Altair R Ambrosio; Iara J de Messias-Reason
Journal:  Front Microbiol       Date:  2017-04-20       Impact factor: 5.640

Review 9.  MBL-associated serine proteases (MASPs) and infectious diseases.

Authors:  Marcia H Beltrame; Angelica B W Boldt; Sandra J Catarino; Hellen C Mendes; Stefanie E Boschmann; Isabela Goeldner; Iara Messias-Reason
Journal:  Mol Immunol       Date:  2015-04-08       Impact factor: 4.407

10.  Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis.

Authors:  Rhea Bhargava; Sylvain Lehoux; Kayaho Maeda; Maria G Tsokos; Suzanne Krishfield; Lena Ellezian; Martin Pollak; Isaac E Stillman; Richard D Cummings; George C Tsokos
Journal:  JCI Insight       Date:  2021-05-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.